The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

Francini, Edoardo; Ou, Fang‐Shu; Lazzi, Stefano; Petrioli, Roberto; Multari, Andrea Giovanni; Pesola, Guido; Messuti, Luciana; Colombo, Elena; Livellara, Virginia; Bazzurri, Serena; Cherri, Sara; Miano, Salvatora Tindara; Wolfe, Eric; Alberts, Steven R.; Hubbard, Joleen M.; Yoon, Harry H.; Francini, Guido

doi:10.1016/j.tranon.2020.100973

Cited by 11 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The American Society of Clinical Oncology recommended that patients with a small number of lymph nodes could be considered insufficiently staged to receive adjuvant chemotherapy [35] . A recent study showed that poor prognosis was associated with a low rate of TILs in stage II CRC patients who did not receive adjuvant therapy [36] , which is consistent with our result. We found that a patient with a low CLR-I score was more likely to benefit from adjuvant chemotherapy, while a patient with a high CLR-I score obtained a longer survival time through an immune response.…”

Section: Discussionsupporting

confidence: 93%

Artificial intelligence for quantifying Crohn’s-like lymphoid reaction and tumor-infiltrating lymphocytes in colorectal cancer

Yang

Zhu

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Artificial intelligence for quantifying Crohn’s-like lymphoid reaction and tumor-infiltrating lymphocytes in colorectal cancer

Yang

Zhu

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…As a core component of the immune response, T cells are present in the tumor microenvironment and determine the efficacy of anti-tumor immunotherapy (2). Immune checkpoints are signaling molecules on the surface of T cells that regulate their activity and participate in the immune response (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism

et al. 2021

View full text Add to dashboard Cite

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an immunosuppressive receptor expressed on the surface of immune cells, suppressing immune responses by activating the intracellular negative regulatory signals. TIGIT plays an important role in the pathogenesis of various tumors, but its immune escape in colorectal cancer remains unclear. We found that the proportion of CD3+TIGIT+ T cells was increased in peripheral blood and cancer tissue in colorectal cancer patients when compared with the healthy donors. These cells exhibited functional defects, low proliferative activity, impaired cytokine production and reduced glucose metabolism. A strong association was also observed between the elevated TIGIT expression and poor prognosis in this cohort. In the in vitro co-culture assays of T cells and tumor cells, the suppressed glucose metabolic activity of T cells was reversed by TIGIT blockade. In addition, this blockade induced the apoptosis and reduced G2/M transit in tumor cells. The antitumor efficacy of TIGIT Ab therapy was further demonstrated in a human colorectal xenograft mice model while co-blockers of TIGIT and PD-1 exhibited synergistic suppressing effects on tumor growth. These results suggest that while TIGIT induces CD3+ T cell dysfunction in colorectal cancer, co-targeting TIGIT and PD-1 can lead to an effective antitumor response and may serve as a novel therapeutic strategy for colorectal patients.

show abstract

“…showed that preoperative low cachexia index (CXI) was an independent and signi cant risk factor for recurrence and poor prognosis, suggesting that cachexia may progress to tumor development and recurrence in patients with extrahepatic biliary tract cancer [10] . Lymphocyte count and serum albumin level were used to re ect systemic immunity and nutritional status of patients [11,12] . Neutrophils and platelets are parts of the in ammatory network, which promotes tumor progression and metastasis.…”

Section: Discussionmentioning

confidence: 99%

The preoperative nutritional and inflammatory indexs as prognostic factors in patients with early-stage resectable extrahepatic bile duct cancer

Zhang,

Gu,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Cancer - associated malnutrition and systemic inflammation have been shown to be strongly linked with poor prognosis in various cancers. The aim of this study was to investigate the prognostic values of the prognostic nutritional index (PNI), nutritional risk index (NRI), advanced lung cancer inflammation index (ALI), and systemic immune-inflammation index (SII) in patients with early-stage resectable extrahepatic bile duct cancer (BDC). Methods A total of 155 early-stage resectable extrahepatic BDC were recruited for this retrospective study. Kaplan-Meier and Cox regression analyses were used to evaluate the prognostic power of preoperative PNI, NRI, ALI, and SII in patients with early-stage extrahepatic BDC. Nomogram was developed based on the results of multivariate Cox analyses and were then validated and calibrated. Results Receiver operating characteristic curve (ROC) analysis identified the optimal cut-off points for PNI, NRI, ALI, and SII were 48.7, 100.5, 49.9, and 659.8. Low PNI, NRI, ALI, and high SII were related to TNM stage (P < 0.05). Kaplan-Meier analysis showed that low PNI, NRI, ALI, and high SII were related to poor overall survival (OS) and recurrence-free survival (RFS) of patients. Multivariate analyses indicated that lymph nodes metastasis, PNI, NRI, ALI, and SII were significant independent factors for OS and RFS. Nomograms were developed to predict OS and RFS for patients with early-stage resectable extrahepatic BDC. Conclusion Preoperative PNI, NRI, ALI, and SII could be used as prospective noninvasive prognostic biomarkers for patients with early-stage resectable extrahepatic BDC.

show abstract

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

Cited by 11 publications

References 21 publications

Artificial intelligence for quantifying Crohn’s-like lymphoid reaction and tumor-infiltrating lymphocytes in colorectal cancer

Artificial intelligence for quantifying Crohn’s-like lymphoid reaction and tumor-infiltrating lymphocytes in colorectal cancer

TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism

The preoperative nutritional and inflammatory indexs as prognostic factors in patients with early-stage resectable extrahepatic bile duct cancer

Contact Info

Product

Resources

About